{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-001294","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.572854+00:00","generated_at":"2026-06-04T23:11:56.128207+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos Q4 net loss $27.9M ($0.22/sh); cash $135.7M; HERALD data expected Q4 2024","bullets":["Cash and investments $135.7M as of Dec 31, 2023; raised $92.1M in Oct 2023 PIPE; runway through end of 2025.","Q4 2023 net loss $27.9M ($0.22/sh) vs $21.9M ($0.51/sh) in Q4 2022; full year net loss $87.7M ($1.36/sh).","ALG-055009 Phase 2a HERALD (MASH) first subject dosed expected Q2 2024; topline data anticipated Q4 2024.","ALG-000184 (CHB) Phase 1b continues; interim data presentations planned at APASL, EASL, AASLD 2024.","ALG-097558 pan-coronavirus protease inhibitor Phase 1 nearing completion; topline data at ECCMID April 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-001294","json":"https://secwatch.observer/filing/0001171843-24-001294.json","markdown":"https://secwatch.observer/filing/0001171843-24-001294.md","text":"https://secwatch.observer/filing/0001171843-24-001294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184324001294/0001171843-24-001294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184324001294/f8k_031124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:11:56.128207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"711d069e09d104ad6c098cd8caff3c4e997b54fa","claim":"Aligos Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $87.7 million, EPS $(1.36).","evidence_excerpt":"Net losses for the year ended December 31, 2023 were $87.7 million or basic and diluted net loss per common share of $(1.36), compared to net losses of $96.0 million or basic and diluted net loss per common share of $(2.25) for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000117184324001294/0001171843-24-001294-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$87.7 million"},{"label":"EPS","value":"$(1.36)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e3687c182412cbf3cfe2a35af4f542a36b234430","claim":"Aligos Therapeutics, Inc. reported the three months ended December 31, 2023 results: net income $27.9 million, EPS $(0.22).","evidence_excerpt":"Net losses for the three months ended December 31, 2023 were $27.9 million or basic and diluted net loss per common share of $(0.22), compared to net losses of $21.9 million or basic and diluted net loss per common share of $(0.51) for the three months ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000117184324001294/0001171843-24-001294-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Net income","value":"$27.9 million"},{"label":"EPS","value":"$(0.22)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}